Keytruda SC: Why a European Launch Needs a Reversal Plan

Week of 5–11 October 2026 · Evidence checked on 11 October · 5-minute read

The Keytruda SC ruling shows how one central company can connect the legal exposure of several markets. A launch plan needs to say who pauses spending, preserves readiness and authorises a restart.

Launch teams know patents differ by country. The Keytruda SC case makes another question concrete: what happens when an order against one company reaches several markets, and its effect can change again as national courts rule?

On 7 October, the District Court of The Hague issued an injunction against Merck Sharp & Dohme B.V. concerning subcutaneous Keytruda in Belgium, Denmark, France, Ireland, Italy, the Netherlands, Sweden and Switzerland. The court found the product within Halozyme’s EP 2 797 622 and rejected MSD’s challenge to the Dutch patent part. Intravenous Keytruda is outside the order. MSD told Fierce Pharma it strongly disagreed. Judgment, paras 5.1–5.3; Halozyme announcement; MSD’s response.

Compliance is due seven days after service. The orders are provisionally enforceable: an appeal does not automatically suspend them. That does not make 7 October the compliance deadline. Judgment, paras 4.111, 4.121 and 5.10.

My take: a coordinated European launch needs country controls and a clear view of the central companies on which those markets depend. The spending and forecast must be able to change when either changes.

The signal: one company connects several markets

The central role. MSD BV holds the EU marketing authorisation and is a named manufacturer responsible for batch release. The court also prohibited it from facilitating affiliate infringement in Belgium, Denmark, France, Ireland and Italy, including through use of its authorisation. The restriction concerns that conduct; holding an authorisation alone is not patent infringement. Judgment, paras 2.5, 4.116 and 5.4; EMA product information, Annex II.

The reversal. For the foreign patent parts, the prohibitions cease if the competent national court invalidates the relevant part, wholly or partly, at first instance or on appeal. They revive if it is subsequently upheld in the relevant respect on appeal or in cassation. Judgment, para 5.6.

The different positions. Germany has a separate preliminary injunction, which MSD has appealed. The UK court recorded a May launch and Halozyme’s submission to revocation of EP 622; litigation continues over a related patent. Neither the UK nor Switzerland falls within the EU authorisation. Judgment, para 2.19; UK judgment, paras 2 and 5; EMA authorisation scope.

For scale, Merck reported $463 million in Keytruda Qlex sales within $8.4 billion of combined Keytruda/Keytruda Qlex sales in Q2 2026. These are global totals, not revenue exposed to this order. Merck Q2 results.

The operator’s take: map the dependency, price the restart

A country-by-country status report can miss how several markets depend on the same company’s permissions and activities. Commercial leaders need that relationship visible before committing resources. The practical output is a list of affected activities, their costs and the person authorised to change them. [Inference]

The court examined MSD’s April statement disputing Halozyme’s account of rapid launch plans in other EU countries where EP 622 applied, alongside its affiliates’ May Swedish and Danish listings. Those commercial steps became evidence in the litigation. The Swedish public listing also moved from available to unavailable and back between 11 May and 15 June. Judgment, paras 2.16–2.17 and 4.106.

That record establishes public actions and status changes. It does not establish hospital disruption or explain MSD’s internal decision process. My operating implication is narrower: in a contested market, the owner approving a listing should understand both the legal position and the commitments the listing creates.

Three decisions before the next launch review

Map central dependencies alongside country status. Ask legal and supply teams which activities of the authorisation holder, release manufacturer or distributor an order could restrict. Identify which markets depend on them and which preparations may continue lawfully.

Name who pauses and who restarts. Legal defines the permitted options. Commercial leadership decides which spending stops, which commitments remain payable and which readiness is worth preserving. Set the authority to change listings, tenders and account communications before the decision becomes urgent. Restart should require a fresh clearance and an accountable commercial owner.

Price the interruption. Model a later start, a pause and a restart separately. Distinguish revenue deferred from revenue lost, and budget for the cost and time of rebuilding readiness. Medical and supply teams should verify continuity independently: an IV formulation outside the order does not establish local stock, capacity or an individual patient’s treatment.

What to watch?

Watch MSD’s next steps and national decisions that alter the restrictions. The July UK judgment listed the related-patent trial in a window beginning 23 November; that is a scheduling window, not a confirmed hearing date. UK judgment, para 8.

For the next launch review: if one central company were restricted tomorrow, which market commitments would continue automatically, and who could change them?

A launch plan is incomplete until it explains how the business will pause and restart.

Independent analysis by Piotr Wrzosinski. Developed with AI assistance for research, source checking and editing. Sources are linked; analysis and recommendations are the author’s interpretation of public evidence. Views are personal.